Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
Status:
Recruiting
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
This is a first-in-human, phase 1, single-center, randomized, double blinded,
placebo-controlled, single dose-escalation study to evaluate the safety, tolerability, PK, of
608 following subcutaneous injection in healthy subjects.